Endotoxin, Neutrophil Function and Albumin in Renal Insufficiency (ENARI)

Chronic kidney disease is widespread in the western world with bacterial infection and sepsis as common complication. It has been shown that innate immune defence, represented by dysfunction of neutrophil granulocytes, is impaired in chronic kidney disease. Another impact of chronic kidney disease on innate immunity is the chronic activation of neutrophils leading to high levels of inflammatory cytokines, thus contributing to protein oxidation. Oxidation of human serum albumin (HSA), the major plasma protein, occurs in chronic kidney disease and leads to further activation of neutrophils. Another important impact of HSA oxidation is the decrease of its binding capacity leading to impaired detoxification ability of albumin. This includes reduced clearance of endotoxin, a major component of the gram negative bacterial cell wall. Circulating endotoxin is recognized by complex formation with lipopolysaccharide binding protein (LBP) followed by binding to CD14 and toll-like receptor (TLR) 4. High systemic endotoxin levels occur in chronic kidney disease and may be the result of decreased clearance ability of HSA and increased gut permeability in combination with intestinal bacterial overgrowth. High systemic endotoxin is associated with worse outcome in several diseases and could be used as predictor for mortality in chronic kidney disease patients.

Endotoxemia in renal insufficiency leads to impaired neutrophil function and to increased albumin oxidation. Oxidized albumin is not able to bind endotoxin adequately any more, which leads to a further increase in oxidative stress and neutrophil dysfunction, resulting in a vicious cycle.

195 patients with renal dysfunction will be enrolled and divided into 5 groups. Additionally, samples of 25 age and sex-matched healthy controls will be collected.

This concept will change the understanding of several aspects of chronic kidney disease and will potentially help to stratify patients into different groups at risk according to their endotoxin status, and their immune and albumin dysfunction. The results of this study will have important implications into the development of novel therapeutic strategies

Study Overview

• Status: Completed
• Conditions: Acute Renal Failure; Chronic Renal Insufficiency

Detailed Description

Laboratory methods Endotoxin will be detected by an adapted limulus amoebocyte lysate assay. LBP and sCD14 will be determined by means of ELISA. HPLC will be used to determine nitrate, nitrite, albumin fractions, albumin binding capacity, iNOS expression and energy status of neutrophils. For investigation of oxidation driven by leukocyte derived myeloperoxidase, mass spectrometry analysis will be used. Carbonyl contents of proteins will be detected by ELISA. Neutrophil function and TLR2, 4 and 9 expression will be studied by flow cytometrical analysis. For cell culture tests, freshly isolated neutrophils or differentiated HL60 cells will be used and incubated with albumin and/or endotoxin. Stool samples will be used for 16srDNA sequencing of the gut microbiome.

• Study Type: Observational
• Enrollment (Actual): 239

Contacts and Locations

Study Locations

• Austria
  • Graz, Austria, 8036
    • Department of Internal Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

1. 50 predialytic patients (a) 25 patients with an eGFR between 30 and 45 (KDIGO 3B) and (b) 25 patients with an eGFR between 15 and 30 (KDIGO 4)
2. 50 patients undergoing hemodialysis or hemodiafiltration for ESRD (a) 25 patients under therapy with sevelamer and (b) 25 patients without sevelamer
3. (a) 25 patients undergoing peritoneal dialysis for ESRD without signs of infection and (b) 25 patients undergoing peritoneal dialysis for ESRD with peritonitis
4. 25 patients with acute renal failure
5. 45 patients after kidney transplantation (a) 15 patients with an eGFR > 45, (b) 15 patients with an eGFR between 30 and 45 and (c) 15 patients with an eGFR < 30
6. 25 age and sex-matched healthy controls

Description

Inclusion Criteria:

Age between 18-80 years, informed consent Groups 1a, 1b, 2a, 2b, 3a, 3b Patients with chronic kidney disease as defined previously [65] either

1a) with an eGFR between 30 and 45 (KDIGO 3B)

1. b) with an eGFR between 15 and 30 (KDIGO 4)
2. a) undergoing hemodialysis for ESRD

2b) undergoing hemodiafiltration for ESRD

3a) undergoing peritoneal dialysis for ESRD without signs of infection

3b) undergoing peritoneal dialysis for ESRD with peritonitis ≥2 out of the 4 criteria (>100 leucocytes/50%neutrophils, cloudy peritoneal dialysate, typical clinical presentation with fever and abdominal pain, positive culture from the peritoneal dialysate)

Group 4 Patients with acute kidney injury (AKIN 3 [66] defined as an increase in serum creatinine to 300% (3-fold) from baseline or serum creatinine 4.0 mg/dl with an acute rise of at least 0.5mg/dl or urine output of < 0.3ml/kg/h 24h or anuria 12h) Initiation of acute renal replacement therapy

Group 5 Stable patients after kidney transplantation with either an eGFR > 45, between 30 and 45 or < 30

Group 6: Healthy controls

Exclusion Criteria:

• Malignancy, pregnancy,chronic inflammatory bowel disease, celiac disease, active alcohol abuse, any severe organ dysfunction unrelated to renal dysfunction Groups 1a, 1b, 2a, 2b, 3 Organ transplantation Clinical evidence of active infection (except for group 3b) Treatment with antibiotics within the last 2 weeks (except for group 3b)

Group 4 Preexisting ESRD

Group 5 Clinical evidence of active infection Treatment with antibiotics within the last 2 weeks

Group 6:

Any evidence of acute or chronic disease

Study Plan

How is the study designed?

Number of groups / cohorts

6

Cohorts and Interventions

Group / Cohort
predialytic renal insufficiency; Patents without renal replacement therapy
hemodialysis/hemofiltration patients; patients undergoing regular hemodialysis/hemofiltration
peritoneal dialysis patients; patients undergoing peritoneal dialysis
acute renal failure; patients with acute renal failure
post renal transplantation; patients after renal transplantation
healthy controls; control group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Endotoxin levels (EU/ml and qualitative positive/negative)	Percentage of patients with measurable endotoxin serum levels in each group.	Day 0

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
albumin oxidation (%), albumin binding capacity (ratio), neutrophil function (%),	We want to investigate the following in patients with different stages of chronic renal insufficiency. Albumin oxidation and function in correlation with the endotoxin status Endotoxin binding to albumin Neutrophil function, energy status and NO metabolism in correlation with the endotoxin status	Day 0
microbiome composition	In a subgroup of patients undergoing hemodialysis or peritoneal dialysis we will assess the composition of the gut micro biome in stool samples by 16s rDNA sequencing	Day 0

Collaborators and Investigators

• Sponsor: Vanessa Stadlbauer-Koellner, MD
• Collaborators: Austrian Science Fund (FWF)
• Investigators: Principal Investigator: Vanessa Stadlbauer, MD, Medical Univeristy of Graz

Study record dates

Study Major Dates

• Study Start: July 1, 2011
• Primary Completion (ACTUAL): January 1, 2014
• Study Completion (ACTUAL): December 1, 2015

Study Registration Dates

• First Submitted: May 23, 2011
• First Submitted That Met QC Criteria: May 27, 2011
• First Posted (ESTIMATE): May 30, 2011

Study Record Updates

• Last Update Posted (ACTUAL): October 11, 2017
• Last Update Submitted That Met QC Criteria: October 10, 2017
• Last Verified: October 1, 2017

More Information

Terms related to this study

• Keywords: albumin function; endotoxin; neutrophil function
• Additional Relevant MeSH Terms: Kidney Diseases; Urologic Diseases; Renal Insufficiency, Chronic; Renal Insufficiency; Acute Kidney Injury
• Other Study ID Numbers: P23532

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED